Skip to content

Study · Animal study (in vivo) · rat · 2009

3 results

The microtubule interacting drug candidate NAP protects against kainic acid toxicity in a rat model of epilepsy.

Zemlyak I, Manley N, Vulih-Shultzman I, Cutler AB, Graber K, Sapolsky RM, Gozes I

Journal of neurochemistry3 Oct 2009Cited by 19 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In kainic acid-treated rats, NAP injection into the dentate gyrus partially protected against CA3 neuron death.

    In plain wordsIn rats, NAP partially reduced neuron death compared with kainic acid injury without NAP.

    Peptide
    Davunetide
    Outcome
    DecreaseCA3 neuron death
    Study

    Ratn: not reported in source

    Kainic acid-induced epilepsy
    Comparator
    Kainic acid injury without NAP
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · Injection into the dentate gyrusAs given in this study (Rat).

    Source sentences

    Summary
    Injection of NAP into the dentate gyrus partially protected against kainic acid-induced CA3 neuron death.
    1 context sentence
    Summary · context
    In the current study, kainic acid-treated rats showed epileptic seizures and neuronal death.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In kainic acid-injured rat brains, NAP partly prevented injury-related gene expression changes.

    In plain wordsIn rats, NAP partly prevented gene expression changes compared with kainic acid injury without NAP.

    Peptide
    Davunetide
    Outcome
    DecreaseInjury-related gene expression changes
    Study

    Ratn: not reported in source

    Kainic acid-induced epilepsy
    Comparator
    Kainic acid injury without NAP
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated · Injection into the dentate gyrusAs given in this study (Rat).

    Source sentences

    Summary
    Microarray analysis (composed of > 31 000 probe sets, analyzing over 30 000 transcripts and variants from over 25 000 well-substantiated rat genes) in the kainic acid-injured rat brain revealed multiple changes in gene expression, which were prevented, in part, by NAP treatment.
    1 context sentence
    Summary · context
    In the current study, kainic acid-treated rats showed epileptic seizures and neuronal death.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In kainic acid-injured rat brains, NAP regulated transcripts including activin A receptor, neurotensin and Wolfram syndrome 1 homolog.

    In plain wordsIn rats with kainic acid injury, NAP regulated genes including activin A receptor, neurotensin and Wolfram syndrome 1 homolog.

    Peptide
    Davunetide
    Outcome
    Direction not reportedRegulation of epilepsy-associated transcripts
    Study

    Ratn: not reported in source

    Kainic acid-induced epilepsy
    Comparator
    Kainic acid injury without NAP
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated · Injection into the dentate gyrusAs given in this study (Rat).

    Source sentences

    Summary
    among the transcripts regulated by NAP were key genes associated with proconvulsant properties and with long-lasting changes that underlie the epileptic state
    2 context sentences
    Summary · context
    including activin A receptor (associated with apoptosis), neurotensin (associated with proper neurotransmission) and the Wolfram syndrome 1 homolog (human, associated with neurodegeneration).
    Summary · context
    In the current study, kainic acid-treated rats showed epileptic seizures and neuronal death.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.